Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

By Goldberg Stuart L.   Chen Lei   Guerin Annie   Macalalad Alexander R.   Liu Nathan   Kaminsky Michael   Ericson Solveig G.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1075-1082

Informa Healthcare

Access to resources Recommend Favorite

Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia

By Iqbal Zafar   Siddiqui Rubina T   Qureshi Javed A   Khalid Ahmad M  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 249-254

Future Medicine

Access to resources Recommend Favorite

Development of Chronic Myelocytic Leukemia after Chemotherapy for Malignant Fibrous Histiocytoma

By  

Acta Haematologica, Vol. 109, Iss. 3, 2003-05 ,pp. : 141-144

Karger

Access to resources Recommend Favorite

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 105-108

John Wiley & Sons Inc

Access to resources Recommend Favorite